Phase 3 N=316 Randomized Quadruple-blind Treatment

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Motion Sickness

Bottom Line

View on ClinicalTrials.gov: NCT05903924 ↗

Enrolled (actual)

316

Serious AEs

0.0%

Results posted

Apr 2025

Primary outcome: Primary: Prevention of Vomiting Measured by Vomiting Assessment (VA) — 11; 19; 40 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Tradipitant (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Vanda Pharmaceuticals
Primary completion: Apr 2024

Outcome Measures

Outcome	Result	p-value
PRIMARY Prevention of Vomiting Measured by Vomiting Assessment (VA)	11; 19; 40	—

Summary

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in participants affected by motion sickness during travel

Eligibility Criteria

Inclusion Criteria

History of motion sickness
Age 18-75

Exclusion Criteria

Nausea-inducing disorder other than motion sickness
BMI>40
History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05903924). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.